AR071598A1 - Uso de epotilona dpara el tratamiento de enfermedades asociadas a tau incluso enfermedad de alzheimer - Google Patents
Uso de epotilona dpara el tratamiento de enfermedades asociadas a tau incluso enfermedad de alzheimerInfo
- Publication number
- AR071598A1 AR071598A1 ARP090101472A ARP090101472A AR071598A1 AR 071598 A1 AR071598 A1 AR 071598A1 AR P090101472 A ARP090101472 A AR P090101472A AR P090101472 A ARP090101472 A AR P090101472A AR 071598 A1 AR071598 A1 AR 071598A1
- Authority
- AR
- Argentina
- Prior art keywords
- disease
- dementia
- parkinsonism
- treatment
- including alzheimer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Psychology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Métodos de tratamiento de tauopatías mediante el uso de epotilona D que presenta buena penetracion cerebral, vida media larga y alta retencion selectiva en cerebro, y proporciona terapias efectivas para el tratamiento de tauopatías, incluso la enfermedad de Alzheimer. Reivindicacion 3: El uso de acuerdo con la reivindicacion 1, en donde la enfermedad asociada a Tau se selecciona de demencia frontotemporal, incluso el subtipo de demencia frontotemporal y parkinsonismo ligado al cromosoma 17 (FTDP-17), parálisis supranuclear progresiva, degeneracion corticobasal, enfermedad de Pick y enfermedad argirofílica granulosa, enfermedad de Parkinson, síndrome de Down, parkinsonismo post-encefálico, distrofia miotonica, enfermedad de Niemann-Pick C, demencia pugilística, enfermedad de Blint, una enfermedad prionica, esclerosis lateral amiotrofica, complejo de parkinsonismo-demencia de Guam, esclerosis multiple, glaucoma, retinopatía diabética y dano cerebral traumático.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4772908P | 2008-04-24 | 2008-04-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR071598A1 true AR071598A1 (es) | 2010-06-30 |
Family
ID=40887113
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP090101472A AR071598A1 (es) | 2008-04-24 | 2009-04-24 | Uso de epotilona dpara el tratamiento de enfermedades asociadas a tau incluso enfermedad de alzheimer |
Country Status (26)
Country | Link |
---|---|
US (3) | US20090270465A1 (es) |
EP (1) | EP2276485B1 (es) |
JP (1) | JP5548675B2 (es) |
KR (1) | KR20100137576A (es) |
CN (3) | CN102076339A (es) |
AR (1) | AR071598A1 (es) |
AU (1) | AU2009240538B2 (es) |
BR (1) | BRPI0911482A2 (es) |
CA (1) | CA2722371C (es) |
CL (1) | CL2009000990A1 (es) |
CY (1) | CY1115617T1 (es) |
DK (1) | DK2276485T3 (es) |
EA (1) | EA021758B1 (es) |
ES (1) | ES2501565T3 (es) |
HK (1) | HK1153152A1 (es) |
HR (1) | HRP20140783T1 (es) |
HU (1) | HUE024506T2 (es) |
IL (1) | IL208926A0 (es) |
MX (1) | MX2010011209A (es) |
NZ (1) | NZ588555A (es) |
PL (1) | PL2276485T3 (es) |
PT (1) | PT2276485E (es) |
SI (1) | SI2276485T1 (es) |
TW (1) | TWI472329B (es) |
WO (1) | WO2009132253A1 (es) |
ZA (1) | ZA201007460B (es) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI3327016T1 (sl) | 2006-04-07 | 2021-09-30 | Vertex Pharmaceuticals Incorporated | Priprava modulatorjev prenašalcev z ATP-vezavno kaseto |
US7645789B2 (en) | 2006-04-07 | 2010-01-12 | Vertex Pharmaceuticals Incorporated | Indole derivatives as CFTR modulators |
US10022352B2 (en) | 2006-04-07 | 2018-07-17 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
US8563573B2 (en) | 2007-11-02 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Azaindole derivatives as CFTR modulators |
EP2155197A4 (en) * | 2007-03-09 | 2011-10-12 | Link Medicine Corp | TREATMENT OF LYSOSOMAL STORAGE DISEASES |
WO2009151683A2 (en) | 2008-03-12 | 2009-12-17 | Link Medicine Corporation | Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications |
SI2276485T1 (sl) | 2008-04-24 | 2014-10-30 | Bristol-Myers Squibb Company | Uporaba epotilona D pri zdravljenju Tau- povezanih bolezni, vključno z Alzheimerjevo boleznijo |
EP2358370A2 (en) * | 2008-11-13 | 2011-08-24 | Link Medicine Corporation | Treatment of proteinopathies using a farnesyl transferase inhibitor |
MX2011005096A (es) | 2008-11-13 | 2011-11-18 | Link Medicine Corp | Derivados de azaquinolinona y usos de los mismos. |
US8802868B2 (en) | 2010-03-25 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide |
CA3108488A1 (en) | 2010-04-22 | 2011-10-27 | Vertex Pharmaceuticals Incorporated | Process of producing cycloalkylcarboxamido-indole compounds |
US8563593B2 (en) * | 2010-06-08 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide |
EP2811980A4 (en) * | 2012-01-31 | 2015-12-23 | Cerulean Pharma Inc | POLYMER-AGENT CONJUGATES, PARTICLES, COMPOSITIONS AND METHODS OF USE THEREOF |
SG11201408626YA (en) | 2012-07-03 | 2015-03-30 | Univ Washington | Antibodies to tau |
WO2014014841A1 (en) | 2012-07-16 | 2014-01-23 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions of (r)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration thereof |
IL303422A (en) | 2014-04-15 | 2023-08-01 | Vertex Pharma | Pharmaceutical preparations for the treatment of diseases related to cystic fibrosis transmembrane conductance regulator modulators |
TW202136296A (zh) | 2014-06-27 | 2021-10-01 | 美商C2N醫療診斷有限責任公司 | 人類化抗-tau抗體 |
JP6321521B2 (ja) * | 2014-11-04 | 2018-05-09 | Well Stone 有限会社 | タウ蛋白産生促進剤、タウ蛋白の欠乏に起因する疾患の治療薬・予防薬および治療用・予防用食品組成物 |
CA3028035A1 (en) | 2016-07-14 | 2018-01-18 | Bioarctic Ab | Brain delivery protein |
CA3184960A1 (en) * | 2020-09-02 | 2022-03-10 | Li Tang | Solid oral formulation of utidelone |
CN113005086B (zh) * | 2021-02-01 | 2022-10-28 | 中国科学院遗传与发育生物学研究所 | 埃博霉素D和Apol8在调控神经干细胞定向神经元分化中的应用 |
Family Cites Families (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2809918A (en) | 1955-10-17 | 1957-10-15 | Victor M Hermelin | Sustained release pharmaceutical preparations |
DE2010416B2 (de) | 1970-03-05 | 1979-03-29 | Hoechst Ag, 6000 Frankfurt | Oral anwendbare Arzneiform mit Retardwirkung |
US4728512A (en) | 1985-05-06 | 1988-03-01 | American Home Products Corporation | Formulations providing three distinct releases |
US4794001A (en) | 1986-03-04 | 1988-12-27 | American Home Products Corporation | Formulations providing three distinct releases |
US5225202A (en) | 1991-09-30 | 1993-07-06 | E. R. Squibb & Sons, Inc. | Enteric coated pharmaceutical compositions |
US5580898A (en) * | 1994-05-24 | 1996-12-03 | The Trustees Of The University Of Pennsylvania | Method of stabilizing microtubules |
PT1186606E (pt) | 1995-11-17 | 2004-08-31 | Biotechnolog Forschung Mbh Gbf | Derivados do epotilone sua preparacao e utilizacao |
US6204388B1 (en) | 1996-12-03 | 2001-03-20 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
EP0977563B1 (en) | 1996-12-03 | 2005-10-12 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
US6605599B1 (en) * | 1997-07-08 | 2003-08-12 | Bristol-Myers Squibb Company | Epothilone derivatives |
KR100574454B1 (ko) * | 1997-12-04 | 2006-04-27 | 브리스톨-마이어즈 스퀴브 컴페니 | 옥시라닐 에포틸론을 환원시켜 올레핀계 에포틸론을 제조하는 방법 |
US6320045B1 (en) * | 1997-12-04 | 2001-11-20 | Bristol-Myers Squibb Company | Process for the reduction of oxiranyl epothilones to olefinic epothilones |
WO1999043653A1 (en) | 1998-02-25 | 1999-09-02 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues therof |
US6498257B1 (en) * | 1998-04-21 | 2002-12-24 | Bristol-Myers Squibb Company | 2,3-olefinic epothilone derivatives |
US6380395B1 (en) * | 1998-04-21 | 2002-04-30 | Bristol-Myers Squibb Company | 12, 13-cyclopropane epothilone derivatives |
UA69413C2 (uk) | 1998-05-22 | 2004-09-15 | Брістол-Майерс Сквібб Компані | Фармацевтична композиція, яка містить серцевину та ентеросолюбільну оболонку, фармацевтична композиція у вигляді сфероїдальних гранул, спосіб одержання сфероїдальних гранул та спосіб одержання фармацевтичної композиції |
IL141074A0 (en) | 1998-07-27 | 2002-02-10 | Brosow Joergen | Security paper, method and device for checking the authenticity of documents recorded thereon |
KR100716272B1 (ko) | 1998-11-20 | 2007-05-09 | 코산 바이오사이언시즈, 인코포레이티드 | 에포틸론 및 에포틸론 유도체의 생산을 위한 재조합 방법 및 물질 |
US6410301B1 (en) | 1998-11-20 | 2002-06-25 | Kosan Biosciences, Inc. | Myxococcus host cells for the production of epothilones |
CN1205208C (zh) * | 1999-02-22 | 2005-06-08 | 生物技术研究股份有限公司 | C-21修饰的环氧噻酮类化合物 |
US6998256B2 (en) | 2000-04-28 | 2006-02-14 | Kosan Biosciences, Inc. | Methods of obtaining epothilone D using crystallization and /or by the culture of cells in the presence of methyl oleate |
US8618085B2 (en) * | 2000-04-28 | 2013-12-31 | Koasn Biosciences Incorporated | Therapeutic formulations of desoxyepothilones |
US20020137152A1 (en) | 2000-07-25 | 2002-09-26 | Daniel Santi | Fermentation process for epothilones |
JP3604337B2 (ja) * | 2000-10-03 | 2004-12-22 | 古河電気工業株式会社 | 絶縁電線の製造方法 |
WO2002032844A2 (de) | 2000-10-16 | 2002-04-25 | Morphochem Ag | Epothilone-synthesebausteine iii und iv: unsymmetrisch substituierte acyloine und acyloinderivate, verfahren zu deren herstellung sowie verfahren zur herstellung von epothilon b, d und epothilonderivaten |
TW476749B (en) * | 2000-11-17 | 2002-02-21 | Nat Science Council | Process for preparing 2,6-dimethylphenol |
FR2817117B1 (fr) | 2000-11-24 | 2005-11-04 | Commissariat Energie Atomique | Mammiferes non-humains transgeniques ou recombinants et leurs applications dans le criblage de medicaments utiles dans les desordres psychoactifs |
WO2002058699A1 (en) | 2001-01-25 | 2002-08-01 | Bristol-Myers Squibb Company | Pharmaceutical forms of epothilones for oral administration |
WO2002062293A2 (en) * | 2001-02-02 | 2002-08-15 | The Regents Of The University Of California | Coumarin compounds as microtubule stabilizing agents and therapeutic uses thereof |
MXPA03010909A (es) * | 2001-06-01 | 2004-02-17 | Bristol Myers Squibb Co | Derivados de epotilona. |
ATE380861T1 (de) | 2002-02-25 | 2007-12-15 | Kosan Biosciences Inc | Modulation der verteilung artverwandter sekundärer metaboliten |
US7082674B2 (en) * | 2002-02-27 | 2006-08-01 | Sumitomo Heavy Industries, Ltd. | Method for winding a single coil of a coil unit for a linear motor |
EP1340498A1 (en) * | 2002-03-01 | 2003-09-03 | Schering Aktiengesellschaft | Use of epothilones in the treatment of brain diseases associated with proliferative processes |
AU2003218107A1 (en) * | 2002-03-12 | 2003-09-29 | Bristol-Myers Squibb Company | C12-cyano epothilone derivatives |
DE60330651D1 (en) * | 2002-03-12 | 2010-02-04 | Bristol Myers Squibb Co | C3-cyanoepothilonderivate |
DK1521752T3 (da) | 2002-07-15 | 2009-06-22 | Helmholtz Infektionsforschung | Makrocykliske forbindelser til behandling af cancer |
AU2003260723A1 (en) | 2002-08-17 | 2004-03-03 | The Queens Universlty Of Belfast | Use of vinca alkaloyds, taxane, cryptophycine, ephitoline or eleutherobine for treating alzheimer |
RU2368661C2 (ru) | 2002-09-23 | 2009-09-27 | Бристол-Маерс Сквибб Компани | Способы получения, выделения и очистки эпотилона b и рентгеноструктурные кристаллические структуры эпотилона в |
WO2004087673A2 (en) * | 2003-03-28 | 2004-10-14 | Sloan-Kettering Institute For Cancer Research | Migrastatin analogs and uses thereof |
US6954131B2 (en) * | 2003-04-02 | 2005-10-11 | Illinois Tool Works Inc. | Electrical reactor assembly having center taps |
MXPA06003835A (es) * | 2003-10-09 | 2006-06-14 | Kosan Biosciences Inc | Formulaciones terapeuticas. |
EP1559447A1 (en) * | 2004-01-30 | 2005-08-03 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Use of epothilones in the treatment of neuronal connectivity defects such as schizophrenia and autism |
WO2006009178A1 (ja) | 2004-07-20 | 2006-01-26 | Toshinori Kato | 生体機能診断装置、生体機能診断方法、生体用プローブ、生体用プローブ装着具、生体用プローブ支持具及び生体用プローブ装着支援具 |
WO2006033913A2 (en) * | 2004-09-16 | 2006-03-30 | Synta Pharmaceuticals Corp. | Bis (thio-hydrazide amides) for treament of hyperplasia |
TW200817348A (en) * | 2006-08-21 | 2008-04-16 | Synta Pharmaceuticals Corp | Compounds for the treatment of proliferative disorders |
EP2061451A2 (en) * | 2006-08-21 | 2009-05-27 | Synta Pharmaceuticals Corporation | Bis(thiohydrazide amides) for treating melanoma |
BRPI0716435A2 (pt) * | 2006-08-21 | 2014-03-04 | Synta Pharmaceuticals Corp | Compostos para o tratamento de doenças proliferativas |
SI2276485T1 (sl) | 2008-04-24 | 2014-10-30 | Bristol-Myers Squibb Company | Uporaba epotilona D pri zdravljenju Tau- povezanih bolezni, vključno z Alzheimerjevo boleznijo |
-
2009
- 2009-04-24 SI SI200931008T patent/SI2276485T1/sl unknown
- 2009-04-24 EP EP09735906.1A patent/EP2276485B1/en active Active
- 2009-04-24 TW TW98113762A patent/TWI472329B/zh not_active IP Right Cessation
- 2009-04-24 BR BRPI0911482A patent/BRPI0911482A2/pt not_active IP Right Cessation
- 2009-04-24 CL CL2009000990A patent/CL2009000990A1/es unknown
- 2009-04-24 WO PCT/US2009/041634 patent/WO2009132253A1/en active Application Filing
- 2009-04-24 DK DK09735906.1T patent/DK2276485T3/da active
- 2009-04-24 EA EA201001695A patent/EA021758B1/ru not_active IP Right Cessation
- 2009-04-24 CN CN2009801242965A patent/CN102076339A/zh active Pending
- 2009-04-24 HU HUE09735906A patent/HUE024506T2/en unknown
- 2009-04-24 CN CN201410305166.4A patent/CN104116736A/zh active Pending
- 2009-04-24 CN CN201510082526.3A patent/CN104666297A/zh active Pending
- 2009-04-24 US US12/429,492 patent/US20090270465A1/en not_active Abandoned
- 2009-04-24 AU AU2009240538A patent/AU2009240538B2/en not_active Ceased
- 2009-04-24 NZ NZ588555A patent/NZ588555A/en unknown
- 2009-04-24 JP JP2011506476A patent/JP5548675B2/ja not_active Expired - Fee Related
- 2009-04-24 MX MX2010011209A patent/MX2010011209A/es active IP Right Grant
- 2009-04-24 ES ES09735906.1T patent/ES2501565T3/es active Active
- 2009-04-24 PT PT97359061T patent/PT2276485E/pt unknown
- 2009-04-24 PL PL09735906T patent/PL2276485T3/pl unknown
- 2009-04-24 KR KR1020107026208A patent/KR20100137576A/ko not_active Application Discontinuation
- 2009-04-24 CA CA2722371A patent/CA2722371C/en not_active Expired - Fee Related
- 2009-04-24 AR ARP090101472A patent/AR071598A1/es unknown
-
2010
- 2010-10-19 ZA ZA2010/07460A patent/ZA201007460B/en unknown
- 2010-10-25 IL IL208926A patent/IL208926A0/en unknown
-
2011
- 2011-06-01 US US13/150,671 patent/US8673949B2/en active Active
- 2011-07-19 HK HK11107477.4A patent/HK1153152A1/xx not_active IP Right Cessation
-
2014
- 2014-01-23 US US14/162,286 patent/US20140135367A1/en not_active Abandoned
- 2014-08-19 HR HRP20140783AT patent/HRP20140783T1/hr unknown
- 2014-10-10 CY CY20141100830T patent/CY1115617T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR071598A1 (es) | Uso de epotilona dpara el tratamiento de enfermedades asociadas a tau incluso enfermedad de alzheimer | |
CL2009000380A1 (es) | Compuestos derivados de heterociclos, moduladores de beta-amiloide; proceso de preparacion; composicion farmaceutica; y uso en el tratamiento de la enfermedad de alzheimer, angioplastia cerebral amiloide, demencia multiinfarto, sindrome de down, entre otras. | |
MX2020012868A (es) | Metodos y composiciones para trastornos del sue?o y otros trastornos. | |
BR112014027584A2 (pt) | compostos e composições para inibir a atividade de abl1, abl2 e bcr-abl1 | |
BR112012018386A8 (pt) | "inibidores isoindolinona de fosfatidilinositol 3-quinase" | |
CL2011001265A1 (es) | Compuestos derivados de 2h-pirazolo[3,4-d]-pirimidin 4,6(5h,7h)- diona, inhibidores de fosfodiesterasa 1 (pde1); composicion farmaceutica; util en el tratamiento de enfermedades que involucran trastornos relacionados con dopamina d1, tales como parkinson, depresion, narcolepsia, esquizofrenia, entre otros. | |
BR112014026383A2 (pt) | derivados de benzamida para inibir a atividade de abl1, abl2 e bcr-abl1 | |
TN2009000381A1 (en) | C5 antigens and uses thereof | |
CY1109985T1 (el) | Αναστολεις πρωτεασωματος και μεθοδοι χρησης αυτων | |
CL2010001159A1 (es) | Compuestos derivados de 3,8-diazabiciclo[2.4.0]octano y 3,6-diazabiciclo[3.2.0]heptano disustituidos, moduladores del receptor de orexina; composicion farmaceutica; utiles en el tratamiento de trastornos del sueño, trastornos metabolicos, entre otros. | |
NZ591057A (en) | Complement antagonists and uses thereof | |
CL2007001731A1 (es) | Compuestos derivados de imidazo[1,5-a]pirimidina; composicion farmaceutica; y uso para tratar o prevenir un trastorno asociado con el deterioro cognitivo, la enfermedad de alzheimer, demencia senil y demencia asociada con enfermedad de parkinson entre otras. | |
UA109459C2 (xx) | ПОХІДНІ 5,6-ДИГІДРОІМІДАЗО[1,2-a]ПІРАЗИН-8-ІЛАМІНУ, ПРИДАТНІ ЯК ІНГІБІТОРИ БЕТА-СЕКРЕТАЗИ (BACE) | |
CL2007001732A1 (es) | Compuestos derivados de imidazo[1,5-a]pirimidina; composicion farmaceutica; y uso para tratar o prevenir un trastorno asociado con el deterioro cognitivo, la enfermedad de alzheimer, demencia senil y demencia asociada con enfermedad de parkinson entre otras. | |
CL2014000246A1 (es) | Compuestos derivados fenil-3-aza-biciclo[3.1.0]hex-3-il-metanonas, inhibidores del transportador de glicina (glyt1); composicion farmaceutica que los contiene; combinacion farmaceutica; y su uso en el tratamiento de alzheimer, alteraciones cognitivas en esquizofrenia, psicosis, trastornos psiquiatricos, entre otros | |
CL2008002809A1 (es) | Compuestos derivados de cianoisoquinolina; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una adiccion a las drogas, en el tratamiento de un trastorno neurodegenerativo, como alzheimer, parkinson, demencia, entre otros. | |
BR112014031531A2 (pt) | composto, composição farmacêutica, métodos de tratamento ou prevenção de uma patologia relacionada com ab, e, de tratamento ou prevenção de mal de alzheimer em um paciente em necessidade do mesmo | |
AU2011305525A8 (en) | Modulators of the GPR119 receptor and the treatment of disorders related thereto | |
MA45504B1 (fr) | Utilisation d'inhibiteurs de télomérase pour le traitement de troubles myéloprolifératifs et de néoplasies myéloprolifératives | |
ATE507214T1 (de) | Neuartige serotonin-wiederaufnahmehemmer als arzneimittel mit peripheriesystem-beschränkter aktivität | |
MX2015007611A (es) | Parche para tratamiento de enfermades del parpado que contiene clobetasol. | |
MX354127B (es) | Compuestos novedosos para prevenir y/o tratar tesaurismosis lisosomicas y/o trastornos degenerativos del sistema nervioso central. | |
MX340564B (es) | Isoformas de neurregulina solubles activas modificadas post-traduccionalmente. | |
IL179831A0 (en) | Human autism susceptibility gene encoding prkcb1 and uses thereof | |
IL185868A0 (en) | Human autism susceptibility gene encoding a transmembrane protein and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |